MetaCap

Bright Minds Biosciences (DRUG) vs NervGen Pharma (NGEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NervGen Pharma (NGEN) has outperformed Bright Minds Biosciences (DRUG) over the past year, losing 35.0% versus a loss of 65.2%. Over five years, DRUG leads with a -7.3% price change compared with -9.6% for NGEN. Bright Minds Biosciences is the larger company by market cap ($201.2 million vs $198.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DRUG-65.18%NGEN-35.04%
+119%+21%-77%
Nov 21, 20251 yearNov 20, 2026
DRUG-18.73%NGEN-16.85%
+276%+81%-114%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DRUG versus NGEN key metrics
MetricDRUGNGEN
Share price$20.40$1.85
Market cap$201.23M$198.55M
1-day change-1.45%-3.91%
YTD return-73.86%-67.05%
1-year return-65.18%-35.04%
5-year return-7.27%-9.56%
EPS (TTM)$-2.05$-0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$123.75$6.30
52-week low$17.40$1.28
Distance from 52-week high-83.52%-70.71%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+426.18%+442.01%
Average volume173.24K621.66K
Shares outstanding9.86M107.62M
Employees269
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NGEN has outperformed DRUG by 30.1 percentage points over the past year.

About Bright Minds Biosciences

DRUG stock →

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.

Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees

About NervGen Pharma

NGEN stock →

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

DRUG vs NGEN FAQ

Which is bigger, Bright Minds Biosciences or NervGen Pharma?

Bright Minds Biosciences (DRUG) is larger, with a market capitalization of $201.23M compared with $198.55M for NervGen Pharma (NGEN).

Which stock has performed better over the past year, DRUG or NGEN?

NGEN returned -35.04% over the past 12 months, compared with -65.18% for DRUG (price return, excluding dividends). Past performance does not predict future results.

Are Bright Minds Biosciences and NervGen Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons